Our business positioning
As a developer of brand-name agrochemicals, CH Biotech invests in more R&D resources than generics counterparts to ensure a higher success rate. Our focus on R&D is reflected in the following operational characteristics.
|
Our research team accounts for 45% of the overall personnel, including those in our wholly-owned US subsidiary CHB LLC. All of the team members, who hold PhD or Master's degrees, are Taiwan-trained talents with global perspectives. |
|
Annually, we invest approximately 10% of revenues in R&D. |
|
The research team holds meetings with distribution partners around the world on a regular basis to understand market needs first-hand. |
【We pride ourselves on technology and distribution capabilities】
| Marketing channels |
Wider |
Big generics suppliers
Post-patent products
Global distribution channels |
|
Big brand-name suppliers
Patented products
Higher R&D levels
Global distribution channels
 |
| |
|
|
|
|
| |
Narrower |
Small generics suppliers
Post-patent products
Limited distribution channels
|
|
Small brand-name suppliers
Patented products
Higher R&D levels
Limited distribution channels |
| |
|
Lower |
|
Higher |
| |
|
|
|
Technology levels |
Business Model
We operate a three-tier model.
|
Innovation in Taiwan:
We have invested NT$2 billion, or just over US$66.8 million, in building a corporate headquarters and a global research center in Central Taiwan Science Park. Our GLP-certified labs mean that test data are internationally credible, which allows us to register products in major agricultural countries. |
|
Manufacturing in the U.S.:
With production facilities based in California, we are able to cut down on shipping costs and enjoy a price premium that comes with the "Made in USA" label. |
|
Marketing globally:
Through strategic alliances with distributors around the world, we sell products in the US, Canada, Brazil, Australia, Uruguay, Argentina, Chile, South Korea, etc. |